ES2188783T3 - Empleo de una tienotriazolodiazepina para aumentar los niveles de apolipoproteina a-i. - Google Patents

Empleo de una tienotriazolodiazepina para aumentar los niveles de apolipoproteina a-i.

Info

Publication number
ES2188783T3
ES2188783T3 ES96930137T ES96930137T ES2188783T3 ES 2188783 T3 ES2188783 T3 ES 2188783T3 ES 96930137 T ES96930137 T ES 96930137T ES 96930137 T ES96930137 T ES 96930137T ES 2188783 T3 ES2188783 T3 ES 2188783T3
Authority
ES
Spain
Prior art keywords
pct
levels
apolipoprotein
tienotriazolodiazepin
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96930137T
Other languages
English (en)
Inventor
Herman Kempen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2188783T3 publication Critical patent/ES2188783T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

EL USO DEL COMPUESTO 9 METIL 4 FENIL 6H TIENOL [3,2 F] S TRIAZOLO [4,3 A][1,4] DIAZEPINA PARA LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO Y PREVENCION DE ENFERMEDADES QUE ESTAN PROVOCADAS POR BAJOS NIVELES PLASMATICOS DE APOLIPOPROTEINA A-I.
ES96930137T 1995-09-09 1996-08-30 Empleo de una tienotriazolodiazepina para aumentar los niveles de apolipoproteina a-i. Expired - Lifetime ES2188783T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95114163 1995-09-09

Publications (1)

Publication Number Publication Date
ES2188783T3 true ES2188783T3 (es) 2003-07-01

Family

ID=8219597

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96930137T Expired - Lifetime ES2188783T3 (es) 1995-09-09 1996-08-30 Empleo de una tienotriazolodiazepina para aumentar los niveles de apolipoproteina a-i.

Country Status (14)

Country Link
US (1) US5854238A (es)
EP (1) EP0853480B1 (es)
JP (1) JPH11512107A (es)
KR (1) KR19990044460A (es)
CN (1) CN1101680C (es)
AT (1) ATE230600T1 (es)
AU (1) AU725249B2 (es)
BR (1) BR9610390A (es)
CA (1) CA2230477A1 (es)
DE (1) DE69625696T2 (es)
DK (1) DK0853480T3 (es)
ES (1) ES2188783T3 (es)
TR (1) TR199800406T1 (es)
WO (1) WO1997009048A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6253569B1 (en) * 1999-05-07 2001-07-03 James J. Hall Portable storage unit for game animals
WO2003024441A1 (fr) 2001-09-14 2003-03-27 Shionogi & Co., Ltd. Nouvelle utilisation de composes tricycliques
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
AU2005314043A1 (en) 2004-12-06 2006-06-15 The Regents Of The University Of California Methods for improving the structure and function of arterioles
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
ES2448567T3 (es) * 2008-10-30 2014-03-14 Circomed Llc Derivados de la tienotriazoldiazepina activos en apo A
HUE031073T2 (en) 2010-05-14 2017-06-28 Dana Farber Cancer Inst Inc Thieno triazolo-diazepine compounds for the treatment of neoplasia
WO2011143651A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
WO2011143657A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
JP5935030B2 (ja) 2010-05-14 2016-06-15 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 白血病を治療するための組成物および方法
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
MX2016005980A (es) 2013-11-08 2016-12-09 Dana Farber Cancer Inst Inc Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal.
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
MX2016011160A (es) 2014-02-28 2017-04-27 Tensha Therapeutics Inc Tratamiento de afecciones asociadas con la hiperinsulinemia.
WO2016018665A1 (en) 2014-07-31 2016-02-04 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
MX2017001757A (es) 2014-08-08 2017-05-30 Dana Farber Cancer Inst Inc Derivados de dihidropteridinona y sus usos.
WO2016022902A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
PE20171042A1 (es) 2014-10-27 2017-07-19 Tensha Therapeutics Inc Inhibidores del bromodominio
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
KR20180051576A (ko) 2015-09-11 2018-05-16 다나-파버 캔서 인스티튜트 인크. 아세트아미드 티에노트리아졸로디아제핀 및 그의 용도
MX2018003031A (es) 2015-09-11 2018-08-01 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas.
SG11201803210YA (en) 2015-11-25 2018-05-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
CN112312916A (zh) 2018-06-13 2021-02-02 戴布里股份公司 缩合三氮杂卓衍生物的制备及其作为bet抑制剂的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
PH12303A (en) * 1973-02-08 1979-01-16 Hoffmann La Roche Thienotriazolodiazepine derivatives
JPS50100096A (es) * 1974-01-08 1975-08-08

Also Published As

Publication number Publication date
EP0853480B1 (en) 2003-01-08
CA2230477A1 (en) 1997-03-13
DE69625696D1 (de) 2003-02-13
AU725249B2 (en) 2000-10-12
TR199800406T1 (en) 1998-05-21
KR19990044460A (ko) 1999-06-25
US5854238A (en) 1998-12-29
CN1195989A (zh) 1998-10-14
MX9801753A (es) 1998-08-30
WO1997009048A1 (en) 1997-03-13
BR9610390A (pt) 1999-07-06
DE69625696T2 (de) 2003-10-16
CN1101680C (zh) 2003-02-19
AU6930396A (en) 1997-03-27
JPH11512107A (ja) 1999-10-19
ATE230600T1 (de) 2003-01-15
DK0853480T3 (da) 2003-05-05
EP0853480A1 (en) 1998-07-22

Similar Documents

Publication Publication Date Title
ES2188783T3 (es) Empleo de una tienotriazolodiazepina para aumentar los niveles de apolipoproteina a-i.
BR9710994A (pt) Derivados anticonvulsivos úteis no tratamento de obesidade.
DK0840732T3 (da) Substituerede benzolactamforbindelser som substans P-antagonister
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
ATE191218T1 (de) Rapamycin-derivate als immunosuppressoren
TR200101969T2 (tr) Enflamasyon tedavisi için sübstitüe edilmiş benzopiran analogları.
BR9813508A (pt) Inibição de replicação viral associada com membrana
CA2174494A1 (en) Benzofurans
DK0750631T3 (da) Mercaptoacetylamido-1,3,4,5-tetrahydrobenzo[c]azepin-3-ondisulfidderivater som enkephalinase- og ACE-inhibitorer
NO953371L (no) Anvendelse av anti-konvulsiva ved behandling av neuro-AIDS
PT831826E (pt) Composicao farmaceutica que inclui um inibidor de proteinase e um monoglicerideo
NO980296L (no) Forbedrede terapeutiske midler
PT817635E (pt) Utilizacao de compostos de tiazepina e oxazepina para a inibicao do vih, herpesvirus e supressores do sitema imunitario
ATE215084T1 (de) Imidazopyridin-azolidinone
ES2173586T3 (es) Derivados de ciclohexandiol.
UA26459C2 (uk) Іhгібітор впливу амілоїдhих білків
AU3255897A (en) Inhibition of hiv-1 replication by antisense rna expression
DE69619530D1 (de) Zyklische somatostatinanaloge mit wachstumhormon inhibierender aktivität
DE69430074D1 (de) Analgetische 4-arylisoindolen
SE9301831D0 (sv) Pharmaceutical compositions
DE69814401D1 (de) 2,3-benzodiazepin-derivate
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia
KR960700053A (ko) 방사선회복제로서 리루졸의 이용(application of riluzole as a radiorestorer)
SE9500500D0 (sv) Inhibtion of the growth of E. coli
ATE160782T1 (de) Fluoro-nukleosid-reinigung